Recent reports from 46brooklyn, a nonprofit think tank, and IQVIA, a drug industry analytics firm, criticized the financial dynamics of 340B.

Two Reports Critique Financial Dynamics of 340B Program

The 340B program may increase medication costs for self-insured employers, a recent study from a pharmaceutical industry outsourcing and analytics [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at